Go back to trials list
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
Description
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by a blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assay.
Trial Eligibility
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb not amenable to treatment with combined modality chemoradiation (advanced) or Stage IV (metastatic) NSCLC * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 * Measurable disease * Adequate recovery from most recent systemic or local treatment for cancer * Adequate organ function * Life expectancy greater than or equal to (\>/=) 12 weeks * For female participants of childbearing potential and male participants, willingness to use acceptable methods of contraception Exclusion Criteria: * Inability to swallow oral medication * Women who are pregnant or lactating * Symptomatic, untreated CNS metastases * History of malignancy other than NSCLC within 5 years prior to screening with the exception of malignancies with negligible risk of metastasis or death * Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina * Known active or uncontrolled human immunodeficiency virus (HIV) infection * Either a concurrent condition or history of a prior condition that places the patient at unacceptable risk if he/she were treated with the study drug or confounds the ability to interpret data from the study * Inability to comply with other requirements of the protocol
Study Info
Organization
Hoffmann-La Roche
Primary Outcome
Cohort A: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
Interventions
Locations Recruiting
University of California San Diego
United States, California, La Jolla
UC Davis; Comprehensive Cancer Center
United States, California, Sacramento
Rocky Mountain Cancer Center
United States, Colorado, Denver
Eastern Connecticut Hematology and Oncology Associates; (ECHO)
United States, Connecticut, Norwich
SCRI Florida Cancer Specialists South
United States, Florida, Fort Myers
Interested in joining this trial?
Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.
Get the latest thought leadership on your Blood Cancer delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.